Bavarian Nordic A/S ( (BVNRY) ) has released its Q2 earnings. Here is a breakdown of the information Bavarian Nordic A/S presented to its investors.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Bavarian Nordic A/S is a global vaccine company specializing in innovative vaccines for travel health and public preparedness, with a strong portfolio in mpox and smallpox vaccines. In the first half of 2025, the company reported a 33% increase in revenue to DKK 2,998 million, driven by significant growth in its Travel Health and Public Preparedness segments. The Travel Health segment saw a 24% revenue increase primarily due to rabies and tick-borne encephalitis vaccines, while Public Preparedness revenue surged by 51% due to strategic order phasing. The company’s EBITDA reached DKK 961 million, with a margin of 32%. Bavarian Nordic has refined its full-year revenue guidance to DKK 6,000-6,600 million, with an expected EBITDA margin of 40-42% including special items. Looking forward, Bavarian Nordic remains optimistic about its growth strategy, focusing on expanding its commercial footprint and securing additional contracts in its Public Preparedness business.